Introduction
============

Polycystic ovary syndrome (PCOS) is a common reproductive disorder, affecting 5--20% of the reproductive-age female population worldwide ([@b1-mmr-21-05-2138],[@b2-mmr-21-05-2138]). In addition, PCOS is associated with ovulatory dysfunction, abdominal adiposity, insulin resistance, obesity, excessive androgen production and cardiovascular risk factors ([@b3-mmr-21-05-2138]). However, the genetic mechanisms of PCOS remain largely unknown, since the etiology of the disease is very complex and affected both by genomic and environmental factors. Therefore, an improved understanding of the genetic mechanisms of PCOS may provide novel insights into the treatment and diagnosis of PCOS ([@b4-mmr-21-05-2138]).

Recent data have suggested that inheritable epigenetic modifications, including the transcriptional effects of microRNAs and methylation patterns within the DNA, are probable contributors to the heritability of PCOS ([@b5-mmr-21-05-2138]). DNA methylation is an important epigenetic phenomenon modulating gene expression during organismal development ([@b6-mmr-21-05-2138]). It has been reported that decreased methylation levels of the anti-Müllerian hormone (AMH) gene may lead to an increased concentration of AMH in ovarian large-follicle tissues, and this was shown to correlate with the pathogenesis of PCOS ([@b7-mmr-21-05-2138]). Global methylation of peripheral blood DNA was found not to be significantly altered in 20 PCOS patients by comparing with 20 controls, suggesting that specific tissues and target genomic regions are required to further determine whether epigenetic alterations may influence the development of PCOS ([@b8-mmr-21-05-2138]). Genome-wide methylated DNA immunoprecipitation analysis of peripheral blood samples from 10 patients with PCOS and 5 healthy controls revealed that 40 genes were differentially methylated, comparing the PCOS patients with the control subjects ([@b9-mmr-21-05-2138]). In addition, the extent of global DNA methylation of granulosa cells isolated from the follicular fluid samples of patients with PCOS was significantly higher compared with healthy controls, and differentially methylated genes were enriched in transcription factor activity, alternative splicing, sequence-specific DNA binding and embryonic morphogenesis ([@b10-mmr-21-05-2138]). Therefore, epigenetic mechanisms involved in the regulation of gene expression caused by genomic DNA methylation patterns could be of great importance in the pathogenesis of PCOS. Wang *et al* ([@b11-mmr-21-05-2138]) conducted a combined analysis of DNA methylation and transcriptome profiling, although only ovarian tissue samples from three PCOS patients and three cervical cancer patients were included in their study ([@b11-mmr-21-05-2138]). Therefore, further well-designed studies of other specific tissues, and based on relatively larger sample sizes, are urgently required to study the genetic mechanisms of PCOS.

In the present study, paired transcription and methylation profiling data of subcutaneous adipose tissue samples collected from 10 cases of PCOS and 10 healthy controls were available to investigate differences in gene expression and DNA methylation patterns. After the differentially expressed genes (DEGs) and differentially methylated genes (DMGs) has been screened, genes showing a negative correlation between expression levels and methylation levels were retained for the construction of protein-protein interaction (PPI) networks. Functional enrichment analysis was subsequently performed for genes in the PPI network. Additionally, a disease-associated pathway network was also established.

Materials and methods
=====================

### Data collection and preprocessing

The gene transcription dataset (E-MTAB-3768) and the methylation dataset (E-MTAB-3777) used in the present study were retrieved from ArrayExpress (<http://www.ebi.ac.uk/arrayexpress/>). ArrayExpress is a public database of microarray gene expression data at the European Bioinformatics Institute (EBI), and is a generic gene expression database designed to serve the scientific community as a repository for data that support publications ([@b12-mmr-21-05-2138]). E-MTAB-3768 consists of transcription profiling data of subcutaneous adipose tissue samples collected from 23 cases of PCOS and 13 healthy controls, generated by the platform, Illumina HumanHT-12_V4 (<https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-3768/>). E-MTAB-3777 contains methylation profiling data of subcutaneous adipose tissue samples collected from 13 cases of PCOS and 11 healthy controls, based on the Infinium HumanMethylation450 BeadChip platform (<https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-3777/>). In the present study, paired DNA methylation and gene expression profiling patterns of samples from 10 PCOS cases and 10 healthy controls were retained for further analysis. The clinical characteristics of these individuals are listed in supplementary [Table SI](#SD1-mmr-21-05-2138){ref-type="supplementary-material"}.

After the original .txt files for E-MTAB-3768 were downloaded, Linear Models for Microarray Analysis (Limma) package (version 3.32.5, <http://bioconductor.org/packages/release/bioc/html/limma.html>) in R software ([@b13-mmr-21-05-2138]) was used for log2 conversion, and sequencing data were subsequently normalized using quantile method ([@b14-mmr-21-05-2138]). The annotations for probes (such as 'chromosome', 'gene', and 'gene region information') in the methylation profiling data of E-MTAB-3777 were conducted based on the information supported by annotation platform HumanMethylation450 BeadChip Versuib 1.0 (<https://support.illumina.com.cn/array/array_kits/infinium_humanmethylation450_beadchip_kit>).

### Differential expression and methylation analysis

Limma package ([@b15-mmr-21-05-2138]) was used to perform differential expression and methylation analyses between PCOS samples and healthy control samples. Statistical P-values were obtained by Limma package and adjusted into the false discovery rate (FDR) using the Benjamini-Hochberg method ([@b16-mmr-21-05-2138]). The thresholds for screening DEGs and DMGs were set as FDR\<0.05 and \|log~2~ fold-change (FC)\|\>0.263 ([@b17-mmr-21-05-2138]).

In addition, the expression and methylation levels of screened DEGs and DMGs in each sample were hierarchically clustered using the pheatmap package (version 1.0.8; <http://cran.r-project.org/package=pheatmap>) ([@b18-mmr-21-05-2138]) in R based on the encyclopedia of distances ([@b19-mmr-21-05-2138]) to observe the differences in expression and methylation levels.

### Integrated analysis of DEGs and DMGs

Overlapping genes between DEGs and DMGs were retained to perform subsequent correlation analysis. Gene Ontology (GO) functional analysis \[categories: Biology process (BP), molecular function (MF) and cellular component (CC)\] and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis according to Database for Annotation, Visualization and Integrated Discovery (DAVID) were performed for genes that were identified having negative correlation between their expression levels and methylation levels ([@b20-mmr-21-05-2138],[@b21-mmr-21-05-2138]). P\<0.05 was set as the threshold value.

### PPI network construction and analysis

Direct (physical) and indirect (functional) PPI interactions for the above genes with negative correlation between expression levels and methylation levels were aggregated using STRING (<http://string-db.org/>), which is a database of known and predicted PPIs ([@b22-mmr-21-05-2138]). The cut-off criterion was set as an interaction score ≥0.4. The PPI network was constructed by integrating the PPIs together using the platform, Cytoscape (<http://www.cytoscape.org/>) ([@b23-mmr-21-05-2138]). Subsequently, genes in the constructed PPI network were used for GO annotation and KEGG pathway enrichment analysis.

### Disease-associated pathway network

Genes and KEGG pathways directly associated with PCOS were searched from the Comparative Toxicogenomics Database (CTD, <http://ctd.mdibl.org/>) ([@b24-mmr-21-05-2138]) using the key words 'polycystic ovary syndrome'. The overlapped genes and pathways were retained to construct the disease-associated pathway network.

Results
=======

### Differential expression and methylation analysis

After data preprocessing, 1,275 DEGs (527 downregulated and 748 upregulated) and 556 DMGs (384 downregulated and 172 upregulated) were respectively identified from transcription and methylation profiling data. The color contrast in hierarchically clustering heat-maps for DEGs or DMGs indicated clear differences in the transcription or methylation levels between PCOS and healthy control samples ([Fig. 1](#f1-mmr-21-05-2138){ref-type="fig"}).

### Integrated analysis of DEGs and DMGs

Among these obtained DEGs and DMGs, 491 overlapping genes between DEGs and DMGs were identified. Correlation analysis revealed that the expression levels of 237 genes were negatively correlated with their methylation levels ([Fig. 2](#f2-mmr-21-05-2138){ref-type="fig"}). These 491 genes were clearly involved with 17, 7, and 4 GO terms in the BP, CC, and MF categories, respectively. These functions were mainly about regulation of cell proliferation and regulation of apoptosis involving *B4GALT1, ERBB2, PML, ZBTB16, TNFRSF9, CDKN1A, IL12B*, and *F2R* ([Table I](#tI-mmr-21-05-2138){ref-type="table"} and [Fig. 3](#f3-mmr-21-05-2138){ref-type="fig"}). Furthermore, 11 KEGG pathways were enriched, including the mitogen-activated protein kinase (MAPK) (P=4.903×10^−3^), p53 (P=2.107×10^−2^) and Wnt (P=2.958×10^−2^) signaling pathways. In addition, the genes *LAMA1, ERBB2, MYLK* and *SPP1* were found to be involved in the focal adhesion pathway (P=4.673×10^−2^; [Table II](#tII-mmr-21-05-2138){ref-type="table"} and [Fig. 3](#f3-mmr-21-05-2138){ref-type="fig"}).

### PPI network construction and analysis

Based on the information in STRING, the PPI network was constructed with 237 PPIs associated with these 491 overlapping genes, involving 127 genes ([Fig. 4](#f4-mmr-21-05-2138){ref-type="fig"}). The top five hub genes with the highest node degree were *SIRT7* (node degree=13), *CDKN1A* (node degree=11), *HDAC3* (node degree=11), *ZBTB16* (node degree=11) and *POLR2J* (node degree=10). Genes in this PPI network were significantly involved with 8, 9 and 9 GO terms in the BP, CC and MF categories, respectively ([Fig. 5](#f5-mmr-21-05-2138){ref-type="fig"}). These functions were mainly concerned with cellular response to stress (P=4.190×10^−5^), negative regulation of biosynthetic processes (P=1.820×10^−4^), regulation of cell proliferation (P=1.434×10^−3^), membrane-enclosed lumen (P=1.500×10^−7^), intracellular organelle lumen (P=1.950×10^−7^), organelle lumen (P=3.300×10^−7^), nucleotide binding (P=2.349×10^−3^), purine nucleoside binding (P=7.436×10^−3^), and nucleoside binding (P=8.046×10^−3^). The regulation of cell proliferation, regulation of apoptosis, regulation of programmed cell death and regulation of cell death were involved with the genes *RBP4, B4GALT1, ERBB2, PML, ZBTB16, CDKN1A, IL12B* and *F2R* ([Table III](#tIII-mmr-21-05-2138){ref-type="table"}).

Furthermore, 11 KEGG pathways were found to be enriched, including the MAPK signaling pathway (P=1.906×10^−3^; *MAP3K7, RPS6KA5, RPS6KA6, MKNK2, FGF13, PRKACB* and *GADD45A*), p53 signaling pathway (P=6.723×10^−3^; *CDKN1A, GADD45A*, and *TP73*), Wnt signaling pathway (P=8.490×10^−3^; *MAP3K7, CTBP1, FZD3*, and *PRKACB*), neuroactive ligand-receptor interaction (P=3.522×10^−2^; *LEP, S1PR3*, and *F2R*) and Jak-STAT signaling pathway (P=3.876×10-^2^; *LEP* and *IL12B*) ([Table IV](#tIV-mmr-21-05-2138){ref-type="table"}).

### Disease-associated pathway network

A total of 162 KEGG pathways and 44 genes were identified to be associated with PCOS in the CTD. After comparing with the genes in the PPI network, one common gene, *LEP*, was identified. The genes that interacted with *LEP*, along with the pathways involving *LEP* or its associated genes, were used to construct the disease-associated pathway network. Four genes (*SPP1, F2R, IL12B* and *RBP4*) and two important pathways (the Jak-STAT signaling pathway and neuroactive ligand-receptor interaction) were revealed ([Fig. 6](#f6-mmr-21-05-2138){ref-type="fig"}). Both *SPP1* and *RBP4* were found to interact with *LEP*. Three genes, including *F2R, IL12B* and *LEP*, were involved in the Jak-STAT signaling pathway, and *LEP* was also associated with the neuroactive ligand-receptor interaction. Expression levels of *F2R, IL12B, LEP* and *SPP1* were significantly increased in the PCOS samples, and their methylation levels were clearly reduced in PCOS samples. The expression of *RBP4* was found to be downregulated in PCOS samples, whereas methylation of *RBP4* was upregulated ([Fig. 7](#f7-mmr-21-05-2138){ref-type="fig"}).

Discussion
==========

Although large-scale genetic and functional studies have shown that epigenetic mechanisms contributed to the development of PCOS, roles of DNA modification in human PCOS have yet to be completely understood ([@b25-mmr-21-05-2138]). In the present study, 499 genes were identified to have both differential methylation and expression levels. Among these genes, the expression levels of 237 of them were negatively correlated with their methylation levels. One common gene, *LEP*, was identified between genes in the PPI network and genes associated to PCOS in the CTD.

Leptin, a 167-amino-acid peptide hormone, is secreted mainly by adipose tissue, and the placenta is the second leptin-producing tissue in humans ([@b26-mmr-21-05-2138]). Studies have revealed that the serum leptin concentration in patients with PCOS is significantly higher compared with that in non-PCOS controls, and serum leptin levels were correlated with body mass index, metabolic disorder, infertility and insulin resistance ([@b27-mmr-21-05-2138]--[@b29-mmr-21-05-2138]). Nevertheless, the roles of leptin in PCOS pathogenesis have yet to be completely elucidated. In the present study, it was revealed that the expression levels of *LEP* were significantly increased in the subcutaneous adipose tissue samples of patients with PCOS, and methylation levels were reduced. The pathway network analysis showed that *LEP* was able to interact with *SPP1* and *RBP4*. The *F2R, IL12B* and *LEP* genes were involved in the Jak-STAT signaling pathway, and *LEP* was also associated with the neuroactive ligand-receptor interaction.

Leptin communicates energy storage status to the central nervous system by binding and activating a cell-surface leptin receptor to regulate appetite, metabolic rate and neuroendocrine function ([@b30-mmr-21-05-2138]). Leptin receptor requires activation of receptor-associated kinases of the Janus family (Jak); subsequently, Jak is autophosphorylated and then tyrosine-phosphorylates various signal transducers and activators of transcription (STATs) ([@b31-mmr-21-05-2138]). Leptin is able to stimulate the Jak-STAT pathway mainly by promoting Jak2 activation, which is the most important Jak isoform to mediate the physiological effects of leptin ([@b32-mmr-21-05-2138]). An increased level of phosphorylation of STAT3 has also been observed in placentas collected from women with PCOS ([@b33-mmr-21-05-2138]). Based on these findings, it is possible to hypothesize that *LEP* serves an important role in the pathophysiology of PCOS via participating in the Jak-STAT signaling pathway.

In the present study, functional enrichment analysis revealed that *IL12B* and *F2R* were also associated with regulation of cell proliferation, regulation of apoptosis, regulation of programmed cell death, regulation of cell death and cell cycle. Meanwhile, *RBP4* was also associated with regulation of cell proliferation, and *SPP1* participated in the pathway of focal adhesion. The expression levels of *F2R, IL12B* and *SPP1* were significantly increased in PCOS samples, while their methylation levels were clearly reduced in the PCOS samples. The expression of *RBP4* was downregulated in PCOS samples, whereas its methylation level was upregulated. PCOS is characterized by hyperandrogenism, which is a fundamental factor in the pathogenesis of PCOS leading to polycystic ovarian morphology and ovulatory dysfunction in women with PCOS ([@b34-mmr-21-05-2138]). Proteins associated with cell survival in the endometria of PCOS may have participatory roles in disruption of the endometrial cell cycle ([@b35-mmr-21-05-2138]). Oocyte apoptosis can trigger atresia during the early phases of follicle development, leading to death of the surrounding granulosa cells that provide oocytes with nutrients and growth regulators, and dysregulation of granulosa cells is responsible for abnormal folliculogenesis and excess production of intraovarian androgens in women with PCOS ([@b36-mmr-21-05-2138],[@b37-mmr-21-05-2138]). It has been shown that the rates of cell death and proliferation in granulosa cell populations were markedly altered in patients with PCOS, which could be due to differential expression of apoptotic effectors and cell survival factors ([@b37-mmr-21-05-2138]). In addition, miR-16 expression was downregulated, and the expression of its target gene, programmed cell death protein 4 (PDCD4), was upregulated in ovarian cortex tissues and the serum of patients with PCOS, and the targeting of PDCD4 by miR-16 may be involved in the pathogenesis of PCOS by inhibiting facilitating cell proliferation, promoting cell cycle progression and facilitating apoptosis of granulosa cells ([@b38-mmr-21-05-2138]). Moreover, testosterone inhibited cell growth and enhanced apoptosis of granulosa cells, possibly by reducing miR-16 and increasing the level of PDCD4. It could be hypothesized that cell proliferation, cell death and the cell cycle all fulfill important roles in abnormal folliculogenesis of PCOS ([@b38-mmr-21-05-2138]). The present study revealed that four aberrantly methylated and expressed genes (*RBP4, SPP1, IL12B* and *F2R*) might also participate in the pathophysiology of PCOS by regulating cell death and the cell cycle as it relates to abnormal folliculogenesis. However, the expression and methylation levels of these important genes, including *RBP4, SPP1, IL12B* and *F2R*, need to be further validated by scientific experiments in the laboratory, such as RT-qPCR.

In conclusion, the present study has revealed numerous important genes with altered DNA methylation levels that may affect mRNA expression. Furthermore, information has tentatively been provided concerning their putative functions and pathways in which they participate. These findings may provide novel insights into the pathogenesis of PCOS and the development of therapeutic intervention strategies.
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![Hierarchically clustering analysis of screened differentially methylated genes and differentially expressed genes. The contrasting colors indicate clear differences in methylation or expression levels between PCOS and healthy control samples. Heat-maps for the (A) differentially methylated and (B) differentially expressed genes are shown. PCOS, polycystic ovary syndrome.](MMR-21-05-2138-g00){#f1-mmr-21-05-2138}
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![Gene Ontology functional and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis for genes with negative correlation between expression levels and methylation levels. BP, biology process; MF, molecular function; CC, cellular component.](MMR-21-05-2138-g02){#f3-mmr-21-05-2138}

![Constructed protein-protein interaction network based on the interactions involving genes with negative correlation between expression levels and methylation levels. As illustrated by the key, the green triangles represent the hypomethylated, upregulated DEGs, whereas the red symbols denote the hypermethylated, downregulated DEGs. DEG, differentially expressed gene.](MMR-21-05-2138-g03){#f4-mmr-21-05-2138}

![GO and KEGG pathway enrichment analysis for genes in the PPI network. Enriched significant functions for genes in the PPI network are shown for the (A) GO and (B) KEGG functional analyses. BP, biology process; MF, molecular function; CC, cellular component; GO, Gene Oncology; KEGG, Kyoto Encyclopedia of Genes and Genomes.](MMR-21-05-2138-g04){#f5-mmr-21-05-2138}

![Pathway network associated with PCOS. Five genes (*LEP, SPP1, F2R, IL12B* and *RBP4*) and two important pathways (the Jak-STAT signaling pathway and neuroactive ligand-receptor interaction) were involved in this pathway network. PCOS, polycystic ovarian syndrome; LEP, leptin; SPP1, secreted phosphoprotein 1; F2R, coagulation factor 2 receptor; IL12B, interleukin-12 subunit β; RBP4, retinol binding protein 4; KEGG, Kyoto Encyclopedia of Genes and Genomes.](MMR-21-05-2138-g05){#f6-mmr-21-05-2138}

![Expression levels of *F2R, IL12B, LEP, RBP4* and *SPP1* in PCOS and healthy control samples. (A) Differences in the expression levels of *F2R, IL12B, LEP, RBP4* and *SPP1* between PCOS and healthy control samples, (B) Differences in methylation levels of *F2R, IL12B, LEP, RBP4* and *SPP1* between PCOS and healthy control samples. Red regular triangles indicate PCOS samples, and green inverted triangles indicate healthy control samples. PCOS, polycystic ovarian syndrome; LEP, leptin; SPP1, secreted phosphoprotein 1; F2R, coagulation factor 2 receptor; IL12B, interleukin-12 subunit β; RBP4, retinol binding protein 4; FDR, false discovery rate.](MMR-21-05-2138-g06){#f7-mmr-21-05-2138}

###### 

GO functional annotations in terms of biology process, molecular function, and cellular component for the 491 overlapping genes between differentially expressed genes and differentially methylated genes.

  Category             Term                                                                     Count   P-value      Genes
  -------------------- ------------------------------------------------------------------------ ------- ------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Biology process      GO:0048609\~reproductive process in a multicellular organism             18      2.390×10-4   *B4GALT1, RBP4, HMGB2, AGFG1, ERBB2, ADCYAP1R1, FIGLA, ZBTB16, ELL3, BOLL, LEP, INHBA, FANCD2, ZMIZ1, WIPF3, ADAMTS1, SPIN4, PNMA1*
                       GO:0032504\~multicellular organism reproduction                          18      2.390×10-4   *B4GALT1, RBP4, HMGB2, AGFG1, ERBB2, ADCYAP1R1, FIGLA, ZBTB16, ELL3, BOLL, LEP, INHBA, FANCD2, ZMIZ1, WIPF3, ADAMTS1, SPIN4, PNMA1*
                       GO:0033554\~cellular response to stress                                  19      4.810×10-4   *HMGB2, UBE2A, DERL1, GEN1, PML, MBD4, RAD9A, SIRT7, TP73, TRIB1, SCAP, PRPF19, CDKN1A, MRPS9, FANCD2, NSMCE1, TDP1, SUPT16H, GADD45A*
                       GO:0009890\~negative regulation of biosynthetic process                  19      5.560×10-4   *HMGB2, CTBP1, CDX4, SIX3, HDAC10, ZNF24, PML, ZHX3, RAD9A, SNW1, SIRT7, DMAP1, ZBTB16, SCAP, INHBA, HHEX, HDAC3, OVOL2, IGFBP5*
                       GO:0042127\~regulation of cell proliferation                             23      6.630×10-4   *B4GALT1, RBP4, UBE2A, CTBP1, PTPRM, ERBB2, PML, ZBTB16, SSR1, TRIB1, LAMA1, HHEX, S1PR3, TNFRSF9, CDKN1A, OSR2, OVOL2, ZMIZ1, PLA2G1B, ADAMTS1, IL12B, F2R, IGFBP5*
                       GO:0010558\~negative regulation of macromolecule biosynthetic process    18      8.940×10-4   *HMGB2, CTBP1, CDX4, SIX3, HDAC10, ZNF24, PML, ZHX3, RAD9A, SNW1, SIRT7, DMAP1, ZBTB16, INHBA, HHEX, HDAC3, OVOL2, IGFBP5*
                       GO:0019953\~sexual reproduction                                          16      1.069×10-3   *B4GALT1, RBP4, HMGB2, AGFG1, ADCYAP1R1, FIGLA, ZBTB16, ELL3, BOLL, LEP, FANCD2, ZMIZ1, WIPF3, ADAMTS1, SPIN4, PNMA1*
                       GO:0031327\~negative regulation of cellular biosynthetic process         18      1.178×10-3   *HMGB2, CTBP1, CDX4, SIX3, HDAC10, ZNF24, PML, ZHX3, RAD9A, SNW1, SIRT7, DMAP1, ZBTB16, INHBA, HHEX, HDAC3, OVOL2, IGFBP5*
                       GO:0051172\~negative regulation of nitrogen compound metabolic process   16      3.578×10-3   *HMGB2, CTBP1, CDX4, SIX3, ZNF24, PML, HDAC10, ZHX3, RAD9A, SNW1, SIRT7, DMAP1, ZBTB16, HHEX, HDAC3, OVOL2*
                       GO:0006355\~regulation of transcription, DNA-dependent                   36      8.581×10-3   *HMGB2, CDX4, IRX2, ZNF557, ZBTB16, DMAP1, ZKSCAN2, OVOL2, PLA2G1B, POU4F1, POU3F1, RFX8, CTBP1, RFX4, SIX3, ZNF24, HDAC10, ZHX3, DMRT2, SNW1, SIRT7, ELL3, ZNF320, TP73, SCAP, RPS6KA5, ASCL2, INHBA, HHEX, HDAC3, RNF4, ZMIZ1, ZNF460, MGA, UNCX, F2R*
                       GO:0042981\~regulation of apoptosis                                      20      9.553×10-3   *B4GALT1, ERBB2, PML, MBD4, RAD9A, ZBTB16, TP73, MAP3K7, INHBA, TNFRSF9, HDAC3, PLEKHG2, CDKN1A, HSP90B1, BNIP1, GSPT1, POU4F1, IL12B, TNFAIP3, F2R*
                       GO:0043067\~regulation of programmed cell death                          20      1.054×10-2   *B4GALT1, ERBB2, PML, MBD4, RAD9A, ZBTB16, TP73, MAP3K7, INHBA, TNFRSF9, HDAC3, PLEKHG2, CDKN1A, HSP90B1, BNIP1, GSPT1, POU4F1, IL12B, TNFAIP3, F2R*
                       GO:0010941\~regulation of cell death                                     20      1.094×10-2   *B4GALT1, ERBB2, PML, MBD4, RAD9A, ZBTB16, TP73, MAP3K7, INHBA, TNFRSF9, HDAC3, PLEKHG2, CDKN1A, HSP90B1, BNIP1, GSPT1, POU4F1, IL12B, TNFAIP3, F2R*
                       GO:0006468\~protein amino acid phosphorylation                           16      3.007×10-2   *CTBP1, ERBB2, MKNK2, PML, ALK, TBCK, TRIB1, RPS6KA5, MAP3K7, RPS6KA6, ADCK1, PLA2G1B, CAMK1, PRKACB, MYLK, F2R*
                       GO:0010604\~positive regulation of macromolecule metabolic process       19      3.329×10-2   *HMGB2, RFX4, SIX3, PML, SIRT7, ELL3, BOLL, TP73, SCAP, HHEX, INHBA, OVOL2, RNF4, ZMIZ1, PLA2G1B, MLST8, POU3F1, IL12B, F2R*
                       GO:0031328\~positive regulation of cellular biosynthetic process         16      3.673×10-2   *HMGB2, RFX4, SIX3, SIRT7, ELL3, TP73, BOLL, SCAP, HHEX, INHBA, OVOL2, RNF4, ZMIZ1, PLA2G1B, IL12B, F2R*
                       GO:0009891\~positive regulation of biosynthetic process                  16      4.086×10-2   *HMGB2, RFX4, SIX3, SIRT7, ELL3, TP73, BOLL, SCAP, HHEX, INHBA, OVOL2, RNF4, ZMIZ1, PLA2G1B, IL12B, F2R*
  Cellular Component   GO:0031974\~membrane-enclosed lumen                                      38      5.070×10-4   *PDP1, HMGB2, PNMA2, POLR2J, PNPT1, FIGLA, PML, ZBTB16, DMAP1, POLR2D, PRPF19, ALAS1, NUMA1, COX6B1, NPM3, POU3F1, ETFB, PDCD11, CTBP1, ZMYM3, HDAC10, RAD9A, MBD4, SNW1, SIRT7, ELL3, RPS6KA5, NVL, CDKN1A, HSP90B1, HDAC3, MRPS9, FANCD2, ZMIZ1, SUPT16H, MATR3, EP400, PNMA1*
                       GO:0070013\~intracellular organelle lumen                                36      9.530×10-4   *PDP1, HMGB2, PNMA2, POLR2J, FIGLA, PML, ZBTB16, DMAP1, POLR2D, PRPF19, ALAS1, NUMA1, NPM3, POU3F1, ETFB, PDCD11, CTBP1, ZMYM3, HDAC10, RAD9A, MBD4, SNW1, SIRT7, ELL3, RPS6KA5, NVL, CDKN1A, HSP90B1, HDAC3, MRPS9, FANCD2, ZMIZ1, SUPT16H, MATR3, EP400, PNMA1*
                       GO:0031981\~nuclear lumen                                                31      1.079×10-3   *HMGB2, PNMA2, POLR2J, FIGLA, PML, ZBTB16, DMAP1, POLR2D, PRPF19, NUMA1, NPM3, POU3F1, PDCD11, CTBP1, ZMYM3, HDAC10, RAD9A, MBD4, SNW1, SIRT7, ELL3, NVL, RPS6KA5, CDKN1A, HDAC3, FANCD2, ZMIZ1, SUPT16H, MATR3, EP400, PNMA1*
                       GO:0043233\~organelle lumen                                              36      1.430×10-3   *PDP1, HMGB2, PNMA2, POLR2J, FIGLA, PML, ZBTB16, DMAP1, POLR2D, PRPF19, ALAS1, NUMA1, NPM3, POU3F1, ETFB, PDCD11, CTBP1, ZMYM3, HDAC10, RAD9A, MBD4, SNW1, SIRT7, ELL3, RPS6KA5, NVL, CDKN1A, HSP90B1, HDAC3, MRPS9, FANCD2, ZMIZ1, SUPT16H, MATR3, EP400, PNMA1*
                       GO:0005654\~nucleoplasm                                                  20      6.379×10-3   *HMGB2, CTBP1, POLR2J, HDAC10, PML, FIGLA, DMAP1, ZBTB16, ELL3, POLR2D, RPS6KA5, PRPF19, HDAC3, NUMA1, CDKN1A, FANCD2, ZMIZ1, SUPT16H, POU3F1, EP400*
                       GO:0043232\~intracellular non-membrane-bounded organelle                 41      2.914×10-2   *HMGB2, PNMA2, USP2, PML, ZBTB16, DMAP1, KIF2C, NUMA1, NPM3, SKA3, NDRG2, TRIP10, CNKSR2, IPP, PDCD11, UBE2A, ZMYM3, RNF19A, PDE4D, SNW1, RAD9A, MBD4, MID1IP1, SIRT7, PALLD, TNKS1BP1, NVL, HDAC3, TUBA8, MRPS9, FANCD2, RPS4Y2, TPPP, SUPT16H, OPHN1, TUBA4A, ARL8B, TNFAIP3, EP400, LCP1, PNMA1*
                       GO:0043228\~non-membrane-bounded organelle                               41      2.914×10-2   *HMGB2, PNMA2, USP2, PML, ZBTB16, DMAP1, KIF2C, NUMA1, NPM3, SKA3, NDRG2, TRIP10, CNKSR2, IPP, PDCD11, UBE2A, ZMYM3, RNF19A, PDE4D, SNW1, RAD9A, MBD4, MID1IP1, SIRT7, PALLD, TNKS1BP1, NVL, HDAC3, TUBA8, MRPS9, FANCD2, RPS4Y2, TPPP, SUPT16H, OPHN1, TUBA4A, ARL8B, TNFAIP3, EP400, LCP1, PNMA1*
  Molecular function   GO:0003677\~DNA binding                                                  43      2.360×10-2   *HMGB2, AGFG1, CDX4, IRX2, POLR2J, ZNF557, FIGLA, PML, DMAP1, ZBTB16, ZKSCAN2, APLP2, PRPF19, KIF2C, OVOL2, SERPINA3, POU4F1, POU3F1, BAHD1, RFX8, CTBP1, RFX4, GEN1, SNAPC1, ZMYM3, SIX3, ZNF24, DMRT2, ZHX3, MBD4, ZNF320, TP73, ASCL2, HHEX, HDAC3, RNF4, TDP1, ZNF460, MGA, TNFAIP3, ZBTB1, EP400, UNCX*
                       GO:0016564\~transcription repressor activity                             11      1.021×10-2   *HHEX, CTBP1, HMGB2, HDAC3, SIX3, PML, ZNF24, HDAC10, SNW1, ZBTB16, DMAP1*
                       GO:0005501\~retinoid binding                                             3       3.174×10-2   *RBP4, RBP7, CYP26A1*
                       GO:0019840\~isoprenoid binding                                           3       3.758×10-2   *RBP4, RBP7, CYP26A1*

GO, Gene Ontology.

###### 

Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis for the 491 overlapping genes between differentially expressed genes and differentially methylated genes.

  Term                                            Count   P-value        Genes
  ----------------------------------------------- ------- -------------- --------------------------------------------------------------------
  hsa04010: MAPK signaling pathway                8       4.903×10^−3^   *MAP3K7, RPS6KA5, RPS6KA6, MKNK2, PLA2G1B, FGF13, PRKACB, GADD45A*
  hsa05200: Pathways in cancer                    9       5.179×10^−3^   *LAMA1, CDKN1A, CTBP1, HSP90B1, ERBB2, PML, FGF13, FZD3, ZBTB16*
  hsa00230: Purine metabolism                     5       1.256×10^−2^   *POLR2J, PNPT1, PDE5A, PDE4D, POLR2D*
  hsa04621: NOD-like receptor signaling pathway   3       1.831×10^−2^   *MAP3K7, HSP90B1, TNFAIP3*
  hsa04115: p53 signaling pathway                 3       2.107×10^−2^   *CDKN1A, GADD45A, TP73*
  hsa04120: Ubiquitin mediated proteolysis        4       2.477×10^−2^   *PRPF19, UBE2D4, UBE2A, PML*
  hsa04520: Adherens junction                     3       2.527×10^−2^   *MAP3K7, PTPRM, ERBB2*
  hsa04310: Wnt signaling pathway                 4       2.958×10^−2^   *MAP3K7, CTBP1, FZD3, PRKACB*
  hsa04540: Gap junction                          3       3.090×10^−2^   *TUBA8, TUBA4A, PRKACB*
  hsa04020: Calcium signaling pathway             4       3.827×10^−2^   *ERBB2, PRKACB, MYLK, F2R*
  hsa04510: Focal adhesion                        4       4.673×1°^−^2   *LAMA1, ERBB2, MYLK, SPP*1

###### 

The GO functional annotations in terms of biology process, molecular function, and cellular component for the genes in the protein-protein interaction network.

  Category             Term                                                       Count   P-value        Genes
  -------------------- ---------------------------------------------------------- ------- -------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Biology process      GO:0033554\~cellular response to stress                    16      4.190×10^−5^   *HMGB2, UBE2A, DERL1, GEN1, PML, RAD9A, SIRT7, TP73, TRIB1, SCAP, PRPF19, CDKN1A, MRPS9, FANCD2, SUPT16H, GADD45A*
                       GO:0009890\~negative regulation of biosynthetic process    15      1.820×10^−4^   *CTBP1, HMGB2, CDX4, HDAC10, PML, ZNF24, RAD9A, SNW1, SIRT7, DMAP1, ZBTB16, SCAP, HHEX, HDAC3, IGFBP5*
                       GO:0042127\~regulation of cell proliferation               16      1.434×10^−3^   *B4GALT1, RBP4, CTBP1, UBE2A, ERBB2, PML, ZBTB16, SSR1, TRIB1, S1PR3, HHEX, CDKN1A, ZMIZ1, IL12B, F2R, IGFBP5*
                       GO:0042981\~regulation of apoptosis                        16      1.770×10^−3^   *B4GALT1, ERBB2, PML, RAD9A, ZBTB16, TP73, MAP3K7, HDAC3, CDKN1A, HSP90B1, GSPT1, BNIP1, POU4F1, IL12B, TNFAIP3, F2R*
                       GO:0043067\~regulation of programmed cell death            16      1.950×10^−3^   *B4GALT1, ERBB2, PML, RAD9A, ZBTB16, TP73, MAP3K7, HDAC3, CDKN1A, HSP90B1, GSPT1, BNIP1, POU4F1, IL12B, TNFAIP3, F2R*
                       GO:0010941\~regulation of cell death                       16      2.021×10^−3^   *B4GALT1, ERBB2, PML, RAD9A, ZBTB16, TP73, MAP3K7, HDAC3, CDKN1A, HSP90B1, GSPT1, BNIP1, POU4F1, IL12B, TNFAIP3, F2R*
                       GO:0007049\~cell cycle                                     15      3.435×10^−3^   *PML, SIRT7, BOLL, TP73, KIF2C, HHEX, HDAC3, CDKN1A, NUMA1, GSPT1, NCAPG2, FANCD2, SKA3, IL12B, GADD45A*
                       GO:0007242\~intracellular signaling cascade                19      1.030×10^−2^   *HMGB2, TLR10, ERBB2, MKNK2, PML, FGF13, RAD9A, TP73, TRIB1, LEP, MAP3K7, RPS6KA5, S1PR3, RPS6KA6, RNF4, ARL8B, PRKACB, F2R, IGFBP5*
  Cellular component   GO:0031974\~membrane-enclosed lumen                        34      1.500×10^−7^   *PDP1, HMGB2, PNMA2, POLR2J, PNPT1, PML, ZBTB16, DMAP1, POLR2D, PRPF19, ALAS1, NUMA1, POU3F1, ETFB, PDCD11, CTBP1, ZMYM3, HDAC10, RAD9A, SNW1, SIRT7, ELL3, RPS6KA5, NVL, HSP90B1, CDKN1A, HDAC3, MRPS9, FANCD2, ZMIZ1, SUPT16H, MATR3, EP400, PNMA1*
                       GO:0070013\~intracellular organelle lumen                  33      1.950×10^−7^   *PDP1, HMGB2, PNMA2, POLR2J, PML, ZBTB16, DMAP1, POLR2D, PRPF19, ALAS1, NUMA1, POU3F1, ETFB, PDCD11, CTBP1, ZMYM3, HDAC10, RAD9A, SNW1, SIRT7, ELL3, RPS6KA5, NVL, HSP90B1, CDKN1A, HDAC3, MRPS9, FANCD2, ZMIZ1, SUPT16H, MATR3, EP400, PNMA1*
                       GO:0043233\~organelle lumen                                33      3.300×10^−7^   *PDP1, HMGB2, PNMA2, POLR2J, PML, ZBTB16, DMAP1, POLR2D, PRPF19, ALAS1, NUMA1, POU3F1, ETFB, PDCD11, CTBP1, ZMYM3, HDAC10, RAD9A, SNW1, SIRT7, ELL3, RPS6KA5, NVL, HSP90B1, CDKN1A, HDAC3, MRPS9, FANCD2, ZMIZ1, SUPT16H, MATR3, EP400, PNMA1*
                       GO:0031981\~nuclear lumen                                  28      1.320×10^−6^   *HMGB2, PNMA2, POLR2J, PML, ZBTB16, DMAP1, POLR2D, PRPF19, NUMA1, POU3F1, CTBP1, PDCD11, ZMYM3, HDAC10, RAD9A, SNW1, SIRT7, ELL3, NVL, RPS6KA5, CDKN1A, HDAC3, FANCD2, ZMIZ1, SUPT16H, MATR3, EP400, PNMA1*
                       GO:0005654\~nucleoplasm                                    19      3.520×10^−5^   *HMGB2, CTBP1, POLR2J, HDAC10, PML, DMAP1, ZBTB16, ELL3, POLR2D, RPS6KA5, PRPF19, HDAC3, NUMA1, CDKN1A, FANCD2, ZMIZ1, SUPT16H, POU3F1, EP400*
                       GO:0043232\~intracellular non-membrane-bounded organelle   36      3.790×10^−5^   *HMGB2, PNMA2, USP2, PML, ZBTB16, DMAP1, KIF2C, NUMA1, SKA3, TRIP10, CNKSR2, PDCD11, UBE2A, ZMYM3, RNF19A, PDE4D, RAD9A, SNW1, SIRT7, PALLD, TNKS1BP1, NVL, HDAC3, TUBA8, MRPS9, FANCD2, RPS4Y2, TPPP, SUPT16H, TUBA4A, OPHN1, ARL8B, TNFAIP3, EP400, LCP1, PNMA1*
                       GO:0043228\~non-membrane-bounded organelle                 36      3.790×10^−5^   *HMGB2, PNMA2, USP2, PML, ZBTB16, DMAP1, KIF2C, NUMA1, SKA3, TRIP10, CNKSR2, PDCD11, UBE2A, ZMYM3, RNF19A, PDE4D, RAD9A, SNW1, SIRT7, PALLD, TNKS1BP1, NVL, HDAC3, TUBA8, MRPS9, FANCD2, RPS4Y2, TPPP, SUPT16H, TUBA4A, OPHN1, ARL8B, TNFAIP3, EP400, LCP1, PNMA1*
                       GO:0044430\~cytoskeletal part                              15      6.493×10^−3^   *CNKSR2, USP2, RNF19A, PDE4D, PALLD, KIF2C, NUMA1, HDAC3, TUBA8, TPPP, TUBA4A, SKA3, ARL8B, TNFAIP3, LCP1*
                       GO:0005856\~cytoskeleton                                   17      3.066×10^−2^   *CNKSR2, USP2, RNF19A, PDE4D, PALLD, KIF2C, TUBA8, NUMA1, HDAC3, TPPP, TUBA4A, OPHN1, SKA3, ARL8B, TNFAIP3, TRIP10, LCP1*
  Molecular function   GO:0000166\~nucleotide binding                             31      2.349×10^−3^   *ERBB2, MKNK2, HELZ, POLR2D, TRIB1, MAP3K7, UBE2D4, KIF2C, ADCK1, ACAD8, PRKACB, UBE2A, CTBP1, SIRT7, ALK, ABCB6, BOLL, ATAD1, RPS6KA5, NVL, RPS6KA6, TUBA8, HSP90B1, GSPT1, PDE5A, TUBA4A, ARL8B, MATR3, MYLK, EP400, ATAD2B*
                       GO:0001883\~purine nucleoside binding                      23      7.436×10^−3^   *UBE2A, ERBB2, MKNK2, HELZ, ALK, ABCB6, ATAD1, TRIB1, RPS6KA5, NVL, MAP3K7, UBE2D4, RPS6KA6, KIF2C, HSP90B1, ADCK1, PDE5A, ACAD8, ARL8B, PRKACB, MYLK, EP400, ATAD2B*
                       GO:0001882\~nucleoside binding                             23      8.046×10^−3^   *UBE2A, ERBB2, MKNK2, HELZ, ALK, ABCB6, ATAD1, TRIB1, RPS6KA5, NVL, MAP3K7, UBE2D4, RPS6KA6, KIF2C, HSP90B1, ADCK1, PDE5A, ACAD8, ARL8B, PRKACB, MYLK, EP400, ATAD2B*
                       GO:0017076\~purine nucleotide binding                      26      8.216×10^−3^   *ERBB2, MKNK2, HELZ, TRIB1, MAP3K7, KIF2C, UBE2D4, ADCK1, ACAD8, PRKACB, UBE2A, ALK, ABCB6, ATAD1, NVL, RPS6KA5, RPS6KA6, HSP90B1, TUBA8, GSPT1, PDE5A, TUBA4A, ARL8B, EP400, MYLK, ATAD2B*
                       GO:0032555\~purine ribonucleotide binding                  25      9.376×10^−3^   *UBE2A, ERBB2, MKNK2, HELZ, ALK, ABCB6, ATAD1, TRIB1, RPS6KA5, NVL, MAP3K7, UBE2D4, RPS6KA6, KIF2C, TUBA8, HSP90B1, ADCK1, GSPT1, PDE5A, TUBA4A, ARL8B, PRKACB, MYLK, EP400, ATAD2B*
                       GO:0032553\~ribonucleotide binding                         25      9.376×10^−3^   *UBE2A, ERBB2, MKNK2, HELZ, ALK, ABCB6, ATAD1, TRIB1, RPS6KA5, NVL, MAP3K7, UBE2D4, RPS6KA6, KIF2C, TUBA8, HSP90B1, ADCK1, GSPT1, PDE5A, TUBA4A, ARL8B, PRKACB, MYLK, EP400, ATAD2B*
                       GO:0030554\~adenyl nucleotide binding                      21      2.425×10^−2^   *UBE2A, ERBB2, MKNK2, HELZ, ALK, ABCB6, ATAD1, TRIB1, RPS6KA5, NVL, MAP3K7, UBE2D4, RPS6KA6, KIF2C, ADCK1, HSP90B1, ACAD8, PRKACB, MYLK, EP400, ATAD2B*
                       GO:0005524\~ATP binding                                    20      2.459×10^−2^   *UBE2A, ERBB2, MKNK2, HELZ, ALK, ABCB6, ATAD1, TRIB1, RPS6KA5, NVL, MAP3K7, UBE2D4, RPS6KA6, KIF2C, ADCK1, HSP90B1, PRKACB, MYLK, EP400, ATAD2B*
                       GO:0032559\~adenyl ribonucleotide binding binding          20      2.782×10^−2^   *UBE2A, ERBB2, MKNK2, HELZ, ALK, ABCB6, ATAD1, TRIB1, RPS6KA5, NVL, MAP3K7, UBE2D4, RPS6KA6, KIF2C, ADCK1, HSP90B1, PRKACB, MYLK, EP400, ATAD2B*

GO, Gene Ontology.

###### 

Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis for the genes in the PPI network.

  Term                                                Count   P-value        Genes
  --------------------------------------------------- ------- -------------- -----------------------------------------------------------
  hsa05200: Pathways in cancer                        8       1.631×10^−3^   *CDKN1A, CTBP1, HSP90B1, ERBB2, PML, FGF13, FZD3, ZBTB16*
  hsa04010: MAPK signaling pathway                    7       1.906×10^−3^   *MAP3K7, RPS6KA5, RPS6KA6, MKNK2, FGF13, RKACB, GADD45A*
  hsa00230: Purine metabolism                         5       2.757×10^−3^   *POLR2J, PNPT1, PDE5A, PDE4D, POLR2D*
  hsa04621: NOD-like receptor signaling pathway       3       5.778×10^−3^   *MAP3K7, HSP90B1, TNFAIP3*
  hsa04115: p53 signaling pathway                     3       6.723×10^−3^   *CDKN1A, GADD45A, TP73*
  hsa04120: Ubiquitin mediated proteolysis            4       6.914×10^−3^   *PRPF19, UBE2D4, UBE2A, PML*
  hsa04310: Wnt signaling pathway                     4       8.490×10^−3^   *MAP3K7, CTBP1, FZD3, PRKACB*
  hsa04540: Gap junction                              3       1.024×10^−2^   *TUBA8, TUBA4A, PRKACB*
  hsa04020: Calcium signaling pathway                 4       1.153×10^−2^   *ERBB2, PRKACB, MYLK, F2R*
  hsa04080: Neuroactive ligand-receptor interaction   3       3.522×10^−2^   *LEP, S1PR3, F2R*
  hsa04630: Jak-STAT signaling pathway                2       3.876×10-^2^   *LEP, IL12B*
